Brief: Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis
04/06/2025 12:16
Sionna Therapeutics Inc SION.O: SIONNA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA FOR NBD1 STABILIZERS SION-719 AND SION-451 AND ADVANCES BOTH PROGRAMS IN CLINICAL DEVELOPMENT FOR CYSTIC FIBROSIS SIONNA THERAPEUTICS INC -NEXT TRIALS TO INITIATE IN SECOND HALF OF 2025 WITH TOPLINE DATA EXPECTED IN MID-2026 SIONNA THERAPEUTICS- SION-719 AND SION-451 WERE GENERALLY WELL TOLERATED AND ACHIEVED DESIRED PHARMACOKINETIC TARGETS Source text: ID:nGNX6TGfN Further company coverage: SION.O
Recent news on Sionna Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial
Sionna hits record low after experimental drug misses mid-stage trial goal
Vertex Pharma rises after rival genetic disorder drug setback